Skip to main content

Align Tech (ALGN) Gets a Hold from Barclays

Tipranks - Tipranks - Fri Feb 6, 1:38AM CST

In a report released today, Glen Santangelo from Barclays maintained a Hold rating on Align Tech, with a price target of $170.00.

Claim 50% Off TipRanks Premium

Santangelo covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Align Tech, and Cencora. According to TipRanks, Santangelo has an average return of 6.1% and a 53.13% success rate on recommended stocks.

In addition to Barclays, Align Tech also received a Hold from TipRanks – PerPlexity’s PerPlexity Medical – Devices in a report issued yesterday. However, today, William Blair maintained a Buy rating on Align Tech (NASDAQ: ALGN).

See today’s best-performing stocks on TipRanks >>

Based on Align Tech’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $995.69 million and a net profit of $56.75 million. In comparison, last year the company earned a revenue of $977.87 million and had a net profit of $115.96 million

Read More on ALGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).